STOCK TITAN

Mereo Biopharma - MREO STOCK NEWS

Welcome to our dedicated page for Mereo Biopharma news (Ticker: MREO), a resource for investors and traders seeking the latest updates and insights on Mereo Biopharma stock.

Mereo Biopharma Group plc (MREO) is a clinical-stage biopharmaceutical leader developing innovative treatments for rare diseases. This dedicated news hub provides investors and industry professionals with timely updates on the company's clinical progress, strategic partnerships, and regulatory developments.

Our curated collection features official press releases and verified news covering critical milestones including clinical trial results, regulatory submissions, and strategic collaborations. Track updates across Mereo's pipeline targeting conditions like osteogenesis imperfecta and alpha-1 antitrypsin deficiency-associated lung disease.

All content undergoes rigorous verification to ensure accuracy and relevance. For comprehensive tracking of Mereo's progress in rare disease therapeutics, bookmark this page for direct access to primary source materials and expert analysis of corporate developments.

Rhea-AI Summary

Mereo BioPharma has announced a partnership with Cancer Focus Fund to evaluate its lead anti-TIGIT antibody, etigilimab, in a Phase 1b/2 clinical study for clear cell ovarian cancer, a rare form of the disease. The study, to be conducted at The University of Texas MD Anderson Cancer Center, will be financed with an upfront consideration of $1.5 million in Mereo shares, along with milestone payments. This collaboration marks the first investment by Cancer Focus Fund, aimed at advancing promising cancer therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.66%
Tags
partnership clinical trial
-
Rhea-AI Summary

Mereo BioPharma Group (NASDAQ: MREO) will present at the 20th Annual Needham Virtual Healthcare Conference on April 12, 2021, at 11:00am Eastern Time. Interested parties can access a live audio webcast via the company’s website, with an archived replay available for two weeks.

Mereo focuses on oncology and rare diseases, featuring six clinical-stage product candidates. Its lead candidate, etigilimab, is in Phase 1b/2 study, while navicixizumab targets late-line ovarian cancer. The company also investigates alvelestat for Alpha-1 antitrypsin deficiency and setrusumab for osteogenesis imperfecta.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
conferences
-
Rhea-AI Summary

Mereo BioPharma Group plc (NASDAQ: MREO) reported a significant net loss of £163.6 million for 2020, compared to a loss of £34.8 million in 2019. Despite the challenges of the pandemic, the company enhanced its pipeline with licensing agreements for setrusumab and navicixizumab, securing substantial milestone payments. Research and development expenses decreased to £16.3 million from £23.6 million in 2019. Cash reserves stand at £23.5 million, with recent financings expected to extend its operational runway into 2024. Mereo aims for substantial milestones in 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.3%
Tags
Rhea-AI Summary

Mereo BioPharma Group plc (NASDAQ: MREO) announced participation of CEO Dr. Denise Scots-Knight in the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021, at 8:00 am ET. A live audio webcast will be available on the company’s website and archived for two weeks post-presentation. Mereo focuses on innovative therapeutics for oncology and rare diseases, with six clinical-stage candidates, including etigilimab and navicixizumab. The company is also advancing alvelestat and setrusumab for rare diseases, aiming for significant outcomes in treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.02%
Tags
conferences
-
Rhea-AI Summary

Mereo BioPharma Group plc (NASDAQ: MREO) has successfully closed its public offering of 39,675,000 American Depositary Shares (ADSs) at $2.90 each. This includes 5,175,000 ADSs from underwriters' options, yielding gross proceeds of $115.1 million. The offering utilized a shelf registration statement, effective since October 21, 2020. Mereo focuses on developing therapeutics for oncology and rare diseases, with multiple product candidates in clinical stages.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.29%
Tags
-
Rhea-AI Summary

Mereo BioPharma Group plc (NASDAQ: MREO) announced the pricing of a public offering of 34.5 million American Depositary Shares (ADSs) at $2.90 each, aiming for gross proceeds of $100.1 million. The offering, fully underwritten by SVB Leerink and others, includes a 30-day option for underwriters to purchase an additional 5.175 million ADSs. The transaction is expected to close on February 12, 2021, pending customary conditions. The funds will support Mereo's clinical development efforts in oncology and rare diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

Mereo BioPharma Group plc (NASDAQ: MREO) announced plans for an underwritten public offering of American Depositary Shares (ADSs), subject to market conditions. The company aims to use the net proceeds for ongoing clinical development of its product candidates and for general corporate purposes. Additionally, underwriters have a 30-day option to purchase up to 15% more ADSs. The offering follows a shelf registration statement declared effective by the SEC in October 2020. SVB Leerink serves as the sole book-running manager, with BTIG and Needham & Company as co-lead managers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Mereo BioPharma Group (MREO) has entered a collaboration with Ultragenyx Pharmaceutical for the development of setrusumab, a monoclonal antibody for osteogenesis imperfecta (OI). Mereo will retain commercial rights in Europe, while Ultragenyx will lead global development and commercialization in other regions. Mereo will receive $50 million upfront and could earn up to $254 million in milestone payments. Setrusumab aims to be the first approved therapy for OI, which affects thousands without existing treatment options. The partnership is expected to focus on pediatric development starting in 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
62.9%
Tags
none
-
Rhea-AI Summary

Mereo BioPharma Group plc (NASDAQ: MREO) announced the cancellation of its Ordinary Shares trading on AIM, effective December 18, 2020. The last trading day on AIM will be December 17, 2020. Mereo will continue to list its American Depositary Shares (ADSs) on Nasdaq. Additionally, the company issued warrants to Silicon Valley Bank and Kreos Capital, allowing them to subscribe for 621,954 ordinary shares at $0.4144 per share. Mereo has also repaid a loan to the Lenders in full.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.46%
Tags
none
Rhea-AI Summary

Mereo BioPharma Group plc (NASDAQ: MREO) announced the appointment of Dr. Suba Krishnan as Senior Vice President of Clinical Development, effective December 7, 2020. Dr. Krishnan brings over 20 years of experience in immuno-oncology, previously serving as Global Program Head at Genmab. Mereo's CEO, Dr. Denise Scots-Knight, expressed confidence in Dr. Krishnan's expertise aiding the advancement of their lead candidate, etigilimab. Mereo is progressing late-stage clinical trials for etigilimab and other therapeutic candidates in oncology and rare diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.92%
Tags
management clinical trial
Mereo Biopharma

Nasdaq:MREO

MREO Rankings

MREO Stock Data

338.67M
148.48M
1.02%
74.31%
4.1%
Biotechnology
Pharmaceutical Preparations
Link
United Kingdom
LONDON